FIELD: pharmaceuticals.
SUBSTANCE: group of inventions relates to liquid pharmaceutical compositions containing semaglutide, an isotonic agent and histidine, as well as to a set containing such a composition. Liquid pharmaceutical composition with GLP-1 activity containing semaglutide, an isotonic agent and histidine, where the histidine concentration is 0.5–15 mM, and where the pH of the composition is in the range of 7.0–7.8. Liquid pharmaceutical composition for the treatment or prevention of diabetes, characterized by the above composition. Liquid pharmaceutical composition for the treatment or prevention of obesity, characterized by the above composition. A set for the treatment or prevention of diabetes or obesity, containing one of the above pharmaceutical compositions and instructions for use.
EFFECT: above group of inventions makes it possible to provide improved chemical and physical stability of the above compositions.
15 cl, 10 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| GLP-1-BASED COMPOSITIONS AND THEIR APPLICATION METHODS | 2018 |
|
RU2777600C2 |
| GLP-1 PEPTIDE SPRAY DRYING METHOD | 2020 |
|
RU2815061C2 |
| SEMAGLUTIDE IN DRUG THERAPY | 2018 |
|
RU2800651C2 |
| SOLID COMPOSITIONS FOR ORAL ADMINISTRATION | 2018 |
|
RU2777206C2 |
| USE OF LONG-ACTING GLP-1 PEPTIDES | 2013 |
|
RU2657573C2 |
| STABLE COMPOSITION OF INSULIN GLULISIN | 2014 |
|
RU2691059C2 |
| STABLE AQUEOUS COMPOSITIONS BASED ON ANTIBODIES | 2014 |
|
RU2763787C2 |
| STABLE FORMULATION ON THE BASIS OF ANTIBODY TO IFNAR1 | 2016 |
|
RU2731737C2 |
| PHARMACEUTICAL COMPOSITION CONTAINING GLP-1 AGONIST AND METHIONINE | 2010 |
|
RU2573995C2 |
| ANTIBODY COMPOSITIONS | 2010 |
|
RU2548772C2 |
